Welcome to our dedicated page for Biolargo news (Ticker: BLGO), a resource for investors and traders seeking the latest updates and insights on Biolargo stock.
BioLargo, Inc. develops and commercializes sustainable technologies across cleantech, environmental engineering, water treatment and life sciences. Company updates commonly cover its Aqueous Electrostatic Concentrator, a PFAS treatment technology designed to remove and collect per- and polyfluoroalkyl substances from liquid streams, as well as engineering services and project work in water, wastewater, remediation and minerals processing.
BioLargo news also follows subsidiary activity, including Clyra Medical Technologies and its FDA-cleared wound care products based on Copper-Iodine Complex Technology, distribution partnerships for ViaCLYR, investor communications, annual operating results, and commercialization updates across medical, environmental and battery-related business lines.
BioLargo, a company focused on sustainable technologies, announced its engineering subsidiary secured a subcontract to provide air quality services to two Arizona U.S. Air Force bases. This contract, worth approximately $812,000 annually, follows another recent contract for three New Mexico Air Force bases, generating an average annual revenue of $650,000. BioLargo's total monthly revenue from these contracts exceeds $100,000. The four-year prime contract ensures pricing but does not guarantee continuation. BioLargo's services include air quality regulatory compliance under the Fence-to-Fence (F2F) support contract through HLTLI Joint Venture.
BioLargo's subsidiary, Clyra Medical Technologies, has selected Keystone Industries to support the manufacturing of its medical products, specifically the Bioclynse surgical wound irrigation solution. Bioclynse is FDA 510(k) cleared, non-cytotoxic, and effective against biofilms, presenting significant benefits for patient outcomes in surgeries and dentistry. Keystone, a global manufacturer with over a century of experience, has committed significant investment in infrastructure to scale up production. Both companies have emphasized the importance of this collaboration for the successful market launch of Bioclynse.
BioLargo (OTCQX:BLGO) has successfully manufactured its first Cellinity™ 'Liquid Sodium' prototype battery cells. The Cellinity battery platform aims to provide safer, long-lasting, and environmentally friendly energy storage alternatives to lithium-ion batteries. These prototype cells will undergo testing and validation to confirm performance claims. Cellinity batteries boast several advantages: safety (no fire or explosion risk), longevity (no performance drop after thousands of cycles), high energy density, and the use of North American-sourced materials without rare-earth elements. Future plans include manufacturing full-scale prototype modules and exploring financing options, focusing on community-based partnerships.
BioLargo (OTCQX:BLGO) announced that its engineering subsidiary has secured a multi-year contract to provide air quality services to three U.S. Air Force bases in New Mexico. The contract, potentially generating $650,000 annually, spans up to five years and represents the company's largest Air Force contract to date. This new agreement adds to BioLargo's ongoing environmental support at six other Air Force bases. The contract ensures regular monthly flat fee revenue over its duration, with annual renewal options. Bhate Environmental Associates is the prime contractor under the Fence-to-Fence (F2F) support contract. BioLargo's President, Randall Moore, emphasized the importance of such long-term contracts for steady income and the commercialization of their cleantech innovations.
BioLargo (OTCQX:BLGO) reported positive operating cash flow of $481,000 and record quarterly revenues of $4,760,000 for Q1 2024, reflecting a 9% increase over Q4 2023 and a 28% increase over Q1 2023. The company's net stockholder's equity rose from $4.2 million to $5.1 million. Despite a net loss of $775,000, this represents a 32% decrease compared to the prior quarter. Significant business developments include launching a water equipment subsidiary and securing key industry leaders on its board. The U.S. EPA's new PFAS regulations could benefit BioLargo's technology. The company continues to invest in scaling up its Bioclynse product line.
BioLargo, Inc. (BLGO) will host an investor webcast and conference call on May 14, 2024, to discuss financial results for Q1 2024, recent milestones, and conduct a Q&A session. The event will be open to the public, covering sustainable technologies for environmental challenges.
Summary not available.
Summary not available.
Summary not available.
Summary not available.